No formal half-life measurement has been published
Tesamorelin is a synthetic modified GHRH analogue clinically approved to reduce visceral adipose tissue (VAT), especially in HIV-associated lipodystrophy, with demonstrated drops in VAT of ~15-18% over 52 weeks
Injectable better for systemic anti-inflammatory effects and internal healing
Rare but serious risks include pancreatitis, gallbladder disease, acute kidney injury (secondary to dehydration from GI effects), and a theoretical thyroid C-cell tumor risk based on rodent data that has not been confirmed in human post-marketing surveillance
Federal health officials and representatives of med spa owners warn consumers that, along with the boom, some facilities are using unlicensed workers to inject unapproved products in unsanitary conditions
Although PEG is not incorporated in conventional liposomes, the addition of cholesterol plays a critical role in maintaining liposomal membrane integrity